Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies

Cardiomyopathies (CMPs) represent a diverse group of heart muscle diseases, grouped into specific morphological and functional phenotypes. CMPs are associated with mutations in sarcomeric and non-sarcomeric genes, with several suspected epigenetic and environmental mechanisms involved in determining penetrance and expressivity. The understanding of the underlying molecular mechanisms of myocardial diseases is fundamental to achieving a proper management and treatment of these disorders. Among these, inflammation seems to play an important role in the pathogenesis of CMPs. The aim of the present study is to review the current knowledge on the role of inflammation and the immune system activation in the pathogenesis of CMPs and to identify potential molecular targets for a tailored anti-inflammatory treatment.

[1]  G. Limongelli,et al.  The hospitalizations in hypertrophic cardiomyopathy: "the dark side of the moon". , 2020, International journal of cardiology.

[2]  G. Limongelli,et al.  Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy , 2020, Genes.

[3]  G. Limongelli,et al.  Unexplained sudden cardiac arrest in children: clinical and genetic characteristics of survivors. , 2020, European journal of preventive cardiology.

[4]  A. Pelliccia,et al.  Yield and clinical significance of genetic screening in elite and amateur athletes. , 2020, European journal of preventive cardiology.

[5]  G. Limongelli,et al.  Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases , 2020, PloS one.

[6]  G. Limongelli,et al.  Genetic analysis resolves differential diagnosis of a familial syndromic dilated cardiomyopathy: A new case of Alström syndrome , 2020, Molecular genetics & genomic medicine.

[7]  S. Priori,et al.  Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy , 2020, Circulation.

[8]  G. Limongelli,et al.  Genotype-Phenotype Correlation: A Triple DNA Mutational Event in a Boy Entering Sport Conveys an Additional Pathogenicity Risk , 2020, Genes.

[9]  C. McCarthy,et al.  Inflammation in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[10]  R. Becker,et al.  Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy , 2020, Journal of Thrombosis and Thrombolysis.

[11]  P. Elliott,et al.  Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. , 2020, International journal of cardiology.

[12]  K. Imanaka-Yoshida,et al.  Inflammation in myocardial disease: From myocarditis to dilated cardiomyopathy , 2019, Pathology international.

[13]  G. Kitas,et al.  Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology , 2019, Diagnostics.

[14]  G. Limongelli,et al.  Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism , 2019, European journal of preventive cardiology.

[15]  M. Link,et al.  2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. , 2019, Heart rhythm.

[16]  G. Valen,et al.  Inhibiting nucleolin reduces inflammation induced by mitochondrial DNA in cardiomyocytes exposed to hypoxia and reoxygenation , 2019, British journal of pharmacology.

[17]  B. Maisch.  Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options , 2019, Front. Cardiovasc. Med..

[18]  P. Libby,et al.  Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure , 2019, Circulation.

[19]  E. Behr,et al.  Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy , 2019, Circulation.

[20]  L. Tavazzi,et al.  The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies , 2018, European heart journal.

[21]  E. Ashley,et al.  Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy , 2017, Journal of the American Heart Association.

[22]  Dave L Dixon,et al.  Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) , 2017, Circulation. Heart failure.

[23]  J. Hare,et al.  Inflammatory Cardiomyopathic Syndromes. , 2017, Circulation research.

[24]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[25]  R. D. de Boer,et al.  From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities , 2017, Current Heart Failure Reports.

[26]  Dobromir Dobrev,et al.  Calcium Signaling and Cardiac Arrhythmias. , 2017, Circulation research.

[27]  S. Iliceto,et al.  Myocarditis: A Clinical Overview , 2017, Current Cardiology Reports.

[28]  William Bracamonte-Baran,et al.  Cardiac Autoimmunity: Myocarditis. , 2017, Advances in experimental medicine and biology.

[29]  A. Murphy,et al.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. , 2017, American journal of translational research.

[30]  L. Calò,et al.  Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. , 2016, Journal of the American College of Cardiology.

[31]  J. Brugada,et al.  Genetic basis of dilated cardiomyopathy. , 2016, International journal of cardiology.

[32]  W. Stevenson,et al.  Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. , 2016, Journal of the American College of Cardiology.

[33]  Robert J. Vincent,et al.  Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction. , 2016, Circulation research.

[34]  Scott W. Rose,et al.  Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study , 2016, Journal of cardiovascular pharmacology.

[35]  A. Kleber,et al.  Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy. , 2016, JCI insight.

[36]  R. D. de Boer,et al.  The fibrosis-cell death axis in heart failure , 2016, Heart Failure Reviews.

[37]  J. Brugada,et al.  A Genetically Vulnerable Myocardium May Predispose to Myocarditis. , 2015, Journal of the American College of Cardiology.

[38]  D. Mann.  Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.

[39]  D. Mann,et al.  Role of innate and adaptive immune mechanisms in cardiac injury and repair , 2015, Nature Reviews Immunology.

[40]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[41]  Dipal M. Patel,et al.  Disease mutations in desmoplakin inhibit Cx43 membrane targeting mediated by desmoplakin–EB1 interactions , 2014, The Journal of cell biology.

[42]  H. Calkins,et al.  Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy , 2014, Science Translational Medicine.

[43]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[44]  W. Pu,et al.  Hippo activation in arrhythmogenic cardiomyopathy. , 2014, Circulation research.

[45]  S. Mavrogeni,et al.  Naxos disease evolution mimicking acute myocarditis: the role of cardiovascular magnetic resonance imaging. , 2013, International journal of cardiology.

[46]  R. Hauer,et al.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.

[47]  Hui-Hua Li,et al.  Macrophage-Stimulated Cardiac Fibroblast Production of IL-6 Is Essential for TGF β/Smad Activation and Cardiac Fibrosis Induced by Angiotensin II , 2012, PloS one.

[48]  M. Laakso,et al.  Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy , 2012, Heart.

[49]  A. Rosenzweig,et al.  The fire within: cardiac inflammatory signaling in health and disease. , 2012, Circulation research.

[50]  D. Wagner,et al.  Neutrophil extracellular traps promote deep vein thrombosis in mice , 2012, Journal of thrombosis and haemostasis : JTH.

[51]  Elizabeth R. Duffy,et al.  Altered Desmosomal Proteins in Granulomatous Myocarditis and Potential Pathogenic Links to Arrhythmogenic Right Ventricular Cardiomyopathy , 2011, Circulation. Arrhythmia and electrophysiology.

[52]  R. Kalluri,et al.  Mechanistic connection between inflammation and fibrosis. , 2010, Kidney international. Supplement.

[53]  R. Frank,et al.  C-Reactive Protein in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Relationship with Ventricular Tachycardia , 2010, Cardiology Research and Practice.

[54]  H. Tan,et al.  Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[55]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.

[56]  S. Heymans,et al.  Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load , 2010, Antiviral therapy.

[57]  A. Davies,et al.  Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis , 2009, Circulation.

[58]  Andrea Frustaci,et al.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.

[59]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[60]  S. Ball,et al.  Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts : Effects of statins and thiazolidinediones , 2007 .

[61]  S. Ball,et al.  Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. , 2007, Cardiovascular research.

[62]  H. Matsubara,et al.  Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. , 2005, International heart journal.

[63]  Y. Mándi,et al.  Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. , 2004, The American journal of cardiology.

[64]  Shizuo Akira,et al.  TLR signaling pathways. , 2004, Seminars in immunology.

[65]  J. Mason.  Myocarditis and dilated cardiomyopathy: an inflammatory link. , 2003, Cardiovascular research.

[66]  G. Thiene,et al.  Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders , 2003, Circulation.

[67]  J. Towbin,et al.  The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[68]  Romuald Wojnicz,et al.  Randomized, Placebo-Controlled Study for Immunosuppressive Treatment of Inflammatory Dilated Cardiomyopathy: Two-Year Follow-Up Results , 2001, Circulation.

[69]  A. Ben-Ze'ev,et al.  Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. , 2000, Journal of cell science.

[70]  T. Mak,et al.  The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease , 2000, Nature Medicine.

[71]  R. Hetzer,et al.  Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. , 2000, Circulation.

[72]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[73]  M. Davies,et al.  Dilated cardiomyopathy: an introduction to pathology and pathogenesis. , 1994, British heart journal.

[74]  A. Matsumori,et al.  Increased circulating cytokines in patients with myocarditis and cardiomyopathy. , 1994, British heart journal.

[75]  D. Corrado,et al.  Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? , 1991, European heart journal.

[76]  K. Leslie,et al.  Progressive interstitial collagen deposition in Coxsackievirus B3-induced murine myocarditis. , 1990, The American journal of pathology.